Linked Life Data

2544288

Source:http://linkedlifedata.com/resource/pubmed/id/2544288

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-7-28
pubmed:abstractText
Subcutaneous GR43175 was examined in patients with acute migraine for efficacy, tolerability and safety in an open, controlled, dose-ranging study. Ten patients with acute, non-medicated, migraine (15 attacks) were assessed for severity of headache and associated symptoms (nausea, vomiting and photophobia). GR43175 plasma samples were monitored serially after dosing. Doses of 2 mg or 3 mg gave rapid relief of all migraine symptoms. Thirteen attacks (86%) had either resolved completely or improved to a mild non-migraine residual headache within 40 min. Treatment was well tolerated at all doses, the only adverse effects being transient pain on injection. Peak plasma concentrations were obtained within 10-20 min; a decline in plasma drug concentration did not result in a relapse in headache severity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0333-1024
pubmed:author
pubmed:issnType
Print
pubmed:volume
9 Suppl 9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
79-82
pubmed:dateRevised
2008-2-11
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine.
pubmed:affiliation
Laboratoire de Pharmacologie, Hôpital Andre Mignot, Versailles.
pubmed:publicationType
Journal Article